Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab rescue therapy in membranous nephropathy after anti-CD20 failure
2021-000835-30Phase 2Active
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of felzartamab in membranous glomerulonephritis (MGN), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Reduction or abrogation of urinary protein excretion. Started Aug 2021; status: active.
02
Drugs
felzartamab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2021-000835-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000835-30.